Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-898

NMRA-898 is structurally distinct from NMRA-861 and is the second M4 PAM in Neumora’s M4 franchise; both programs have potential best-in-class ...
Medscape

Novel Drug With New Mechanism Promising for Parkinson’s Motor Fluctuations

Glovadalen, a novel D1 receptor positive allosteric modulator, is linked to improve OFF time in patients with Parkinson’s ...
Healio

Neurosterix launches with $63 million to advance allosteric modulator therapeutics

Please provide your email address to receive an email when new articles are posted on . A Swiss biopharmaceutical company announced its launch with $63 million in Series A financing for research and ...
Healio

Allosteric modulator nonsuperior to placebo in Parkinson’s disease

Please provide your email address to receive an email when new articles are posted on . Change from baseline in gait variability did not differ between groups, regardless of cognitive load. Treatment ...
MPR

Negative Allosteric Modulator Candidate Misses Endpoints in Social Anxiety Disorder Trial

Topline results were announced from a phase 3 trial evaluating BNC210 in patients with social anxiety disorder.

Biogen's Immunology Pipeline Has Long-Term Potential: Analyst

Biogen gains exclusive rights to Vanqua's oral C5aR1 antagonist, boosting its immunology pipeline with potential across ...
Fierce Biotech

MapLight goes public via $250M IPO to fund Cobenfy competitor

MapLight Therapeutics is heading to the Nasdaq this morning via a $250 million IPO the biotech will use to advance its ...
Nasdaq

Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological Disorders

Geneva, Switzerland and New York, USA, April 3, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company pioneering allosteric modulation-based drug development, ...